A new study confirms that six-month BPaL/M regimens for drug-resistant TB save lives and money. Compared to longer treatments, they cut costs per cure, boost completion rates, and are projected to deliver nearly US$1 billion in economic benefits in South Africa and US$800 million in the Philippines within five years.

PeerLINC’s G-TEC brought together experts from 18 countries to review complex DR-TB cases from the Philippines and India, demonstrating how collective expertise can guide safer and more effective treatment decisions.

PeerLINC Knowledge Hub joined global and national TB leaders at the 31st Philippine Coalition Against Tuberculosis (PhilCAT) Annual Convention, held August 14 to 15. A key focus of the convention was accelerating access to new WHO-recommended regimens for drug-resistant TB (DR-TB).